Tuesday, Jan. 19, 2021 : Issue #1099 DISASTERS AVERTED — Near Miss Case Studies
Errors and Resolutions in the Use of the COVID-19 Vaccine |
|
Letter from the Editor
 There is no doubt that some companies are benefiting from the current pandemic. I am not saying they are gouging patients, but just that the opportunity to market products like PPE and ventilators and supplies is driving giant sales. In addition, if your company happens to have an approved virus vaccine like Pfizer, or a therapy to reduce COVID severity like Gilead, your sales will be through the roof. But what about the rest of Pharma and all the medications for chronic diseases, like hypertension or diabetes, or asthma?
We know that many patients are either stretching their medications or stopping them all together. This has evidently had an effect on the bottom lines of some large pharma companies. Most companies raise their prices every January, and today it was announced that drug prices for already marketed drugs had increased more than in the past 5 years, and more companies than ever announced price increases.
This all means our jobs will be a little harder, and I encourage all of you to help your patients by going the extra step to do the prior authorizations when needed, and using manufacturer buy down programs when possible.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
